IJGII Inernational Journal of Gastrointestinal Intervention

pISSN 2636-0004 eISSN 2636-0012


home All Articles View

Original Article

Int J Gastrointest Interv 2024; 13(1): 16-22

Published online January 31, 2024 https://doi.org/10.18528/ijgii230045

Copyright © International Journal of Gastrointestinal Intervention.

Functional bowel disorders among bariatric surgery candidates before and after surgery: A prospective cohort study

Sharif Yassin1,*, Noa Sori2, Ophir Gilad1, Mati Shnell1, Relly Richer1, Nir Bar3, Yishai Ron3, Nathaniel Aviv Cohen1, Subhi Abu-Abeid4, Danit Dayan4, Shai Meron Eldar4, Shira Zelber-Sagi2, and Sigal Fishman1

1Bariatric Endoscopy Service, Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel
2Department of Nutrition, Health and Behavior, Faculty of Public Health, Haifa University, Haifa, Israel
3Neurogastroenterology and Motility Service, Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel
4Bariatric Surgery Unit, Division of General Surgery, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel

Correspondence to:*Bariatric Endoscopy Service, Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6 Weizman Street, Tel Aviv-Yafo 6423906, Israel.
E-mail address: shariefyas@gmail.com (S. Yassin).

Received: September 8, 2023; Accepted: January 3, 2024

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/bync/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corrigendum: Int J Gastrointest Interv 2024;13:63

Background: Functional bowel disorders (FBDs), including irritable bowel syndrome (IBS), are common worldwide. Recently, increasingly many bariatric surgical procedures have been performed in response to rising obesity rates. However, data on the association between FBDs and bariatric surgery are scarce. We examined the prevalence of FBDs among candidates for bariatric surgery and prospectively investigated the association between FBDs and bariatric surgery.
Methods: This prospective cohort study included 112 bariatric surgery candidates at the Tel Aviv Medical Center from 2019 to 2020. Before and after surgery, patients completed the Rome III questionnaire. Data regarding demographics, socioeconomic status, and gastrointestinal symptoms were recorded. The rates of FBDs—IBS, functional constipation (FC), functional diarrhea (FDi), and unspecified functional bowel disorder (UFBD)—were then compared from before surgery to 6 months after the procedure.
Results: Of 112 candidates with obesity at baseline, 68 underwent surgery and completed the postoperative questionnaire. Overall, the respective prevalence rates of FBDs, IBS, FC, FDi, and UFBD were 37.5%, 2.7%, 17.9%, 5.4%, and 11.6%. Female sex and single status were particularly common among patients with FBDs, whereas divorced status was more frequent in the group without FBDs. However, these factors were not independently associated with FBD presence upon multivariable analysis. IBS was more prevalent after surgery than before (8.8% vs. 1.5%, P = 0.06), but FBDs in general did not share this trend (44.1% vs. 36.8%, P = 0.44).
Conclusion: Bariatric surgery appears to increase the risk of developing IBS, while not impacting the overall risk of FBDs.

Keywords: Bariatric surgery, Irritable bowel syndrome, Obesity, Risk factors

Functional bowel disorders (FBDs) are common conditions, collectively impacting up to one-third of the global population. They lead to diminished quality of life and work productivity, while placing a substantial burden on healthcare systems.14 The Rome III criteria categorize these disorders into several distinct types, including irritable bowel syndrome (IBS), functional constipation (FC), functional diarrhea (FDi), and unspecified FBD (UFBD).

The pathogenesis of FBD is diverse, encompassing abnormalities in motility, visceral sensitivity, brain-gut communication, and psychological distress.5 In recent years, changes in gut immune response, intestinal permeability, and the microbiome of the intestine and colon have been observed in some individuals with IBS, offering additional understanding of the possible pathophysiological mechanisms at play.610 Risk factors for IBS include young age, female sex, family history of IBS, anxiety, and smoking.1113

Obesity affects between 12% and 19.5% of adults, with the highest prevalence found in the sixth and seventh decades of life for women and men, respectively.14,15 Among individuals with obesity, the prevalence of IBS ranges from 11.6% to 24%.16 The role of obesity as a risk factor for FBDs remains unclear.17 One investigation reported that up to 30% of those with morbid obesity have IBS.18 However, a recent comprehensive review of the literature presented mixed findings regarding whether obesity represents a risk factor for IBS onset.16

The escalating rates of obesity around the world have been paralleled by an increase in the number of bariatric surgical procedures performed. Data from the global registry of the International Federation for the Surgery of Obesity and Metabolic Disorders indicate that laparoscopic sleeve gastrectomy (LSG) is the most common, accounting for 46% of bariatric procedures. This is followed by Roux-en-Y gastric bypass (RYGB) (38.2%), mini-gastric bypass (MGB) (7.6%), and gastric banding (5%).19 An expanding body of evidence supports bariatric surgery as the most effective method for achieving substantial weight loss and mitigating comorbidities associated with obesity.20,21 Additionally, improvements in various dimensions of health-related quality of life have been reported.22

Several studies have explored the link between bariatric surgical procedures and the emergence of FBDs, yielding mixed results. IBS has been reported to impact 24% to 29.1% of patients following bariatric surgery, with higher rates among women than men.2325 Furthermore, abdominal bloating and pain are frequently reported after LSG and RYGB, affecting 33.8% and 54.4% of patients, respectively.23,26,27 In one study, only 18.5% of patients who experienced chronic abdominal pain after surgery had reported pain prior to the procedure.23 However, most of these studies were not specifically aimed at investigating the relationship between bariatric surgery and FBD onset, resulting in limited and inconsistent data.

In the present study, our goal was to quantify the prevalence of FBDs at baseline and to characterize risk factors for FBDs among obese candidates for bariatric surgery. Additionally, we aimed to examine the relationship between bariatric surgery and the emergence of FBDs over a 6-month follow-up period. Of note, due to the impact of bariatric surgery on the continuity and function of the upper gastrointestinal (UGI) tract, we intentionally excluded functional UGI disorders from our investigation.

Study design and population

This prospective cohort study enrolled adult patients (aged over 18 years) with obesity who were candidates for bariatric surgery, following their attendance at the Obesity and Pre-Surgery Clinic of the Tel Aviv Medical Center. The inclusion criteria were the ability to complete the study questionnaire and consent to participate in the study. Patients were excluded if they had a known diagnosis of inflammatory bowel disease, previous bariatric surgery, early or late surgical complications necessitating additional surgical or endoscopic interventions or hospitalization, or an objective explanation for their symptoms upon evaluation, such as anastomotic marginal ulcer or dumping syndrome. Eligible candidates were asked to complete the Rome III questionnaire at baseline during a preoperative clinic visit and again via a telephone survey 6 months after surgery.28 This questionnaire was used to assess the presence of FBDs along with additional demographic, medical, and socioeconomic parameters.29 Based on the criteria for IBS diagnosis, responses to the questionnaire were used to classify FBDs into four subgroups: IBS, FC, FDi, and UFBD.30 We omitted questions pertaining to functional UGI disorders, such as functional dyspepsia, as these are commonly observed after bariatric surgery and may related to the surgical procedure itself.27 The use of the Rome III questionnaire was authorized by the Rome Foundation. Additional data were gathered during the preoperative clinic visit and confirmed through the review of electronic medical records. The bariatric procedures included in the study were LSG, RYGB, and MGB.

This study was approved by the Tel Aviv Medical Center review board (protocol no. 0748-18) and conformed to the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants.

Definitions of FBD according to Rome III criteria

IBS is characterized by recurrent abdominal pain or discomfort occurring at least 3 days per month over the prior 3 months. This discomfort is associated with two or more of the following symptoms: alleviation of pain upon defecation, the onset of symptoms coinciding with a change in stool frequency, and the onset of symptoms coinciding with a change in stool form. FC is defined by difficult, infrequent, or incomplete bowel movements, while FDi involves the recurrent passage of loose or watery stools; both of these conditions occur without associated pain or discomfort. UFBD is diagnosed when patients experience functional abdominal symptoms but do not meet the criteria for IBS, FDi, or FC.30

Statistical analysis

Differences in continuous variables were assessed using the Student t test for parametric data and the Mann-Whitney test for non-parametric data. For categorical variables, differences were examined using the chi-square test or Fisher exact test. Logistic regression was applied to evaluate associations between baseline characteristics and the odds of FBD presence, both before and after surgery. Significant factors were then included in a multivariable analysis. Changes in outcomes between preoperative and postoperative states were assessed using the McNemar test. A P-value of less than 0.05 was considered to indicate statistical significance for all tests. All statistical analyses were conducted using IBM SPSS (version 26.0; IBM Corp.).

A total of 112 consecutive bariatric surgery candidates at the Tel-Aviv Medical Center bariatric clinic completed the initial questionnaire. The prospective analysis encompassed 68 patients who underwent surgery and submitted the postoperative questionnaire. Regarding the type of procedure, 42 patients underwent MGB, 5 underwent RYGB, and 21 underwent LSG. The remaining participants were either lost to follow-up or did not proceed with surgery for various reasons (Fig. 1).

Figure 1. Flow chart of the study population. COVID-19, coronavirus disease 2019; MGB, mini-gastric bypass; RYGB, Roux-En-Y gastric bypass; LSG, laparoscopic sleeve gastrectomy.

FBDs among bariatric surgery candidates

The cohort comprised 112 patients (64.3% female; mean age, 41.1 ± 13.0 years), with a mean body mass index (BMI) of 42.5 ± 5.3 kg/m2. Of these, 42 (37.5%) were found to have FBDs. FC was the most frequently observed disorder, while IBS was the least common (Table 1). Relative to patients without FBDs, higher proportions of patients with FBDs were female (76.2% vs. 22.9%, P = 0.04) and single (45.2% vs. 27.1%, P = 0.05). Notably, a larger percentage of divorced individuals was observed in the group without FBDs (17.1% vs. 2.4%, P = 0.03) (Supplementary Table 1). However, after conducting a multivariable analysis that adjusted for age, sex, marital status, and BMI (ranging from 33.9 kg/m2 to 60.2 kg/m2), none of these factors were found to be independently associated with the presence of FBDs.

Table 1 . FBDs, Demographics, and Medical Characteristics among Candidates for Bariatric Surgery.

ParameterValue (n = 112)
IBS3 (2.7)
FC20 (17.9)
FDi6 (5.4)
UFBD13 (11.6)
Total FBDs42 (37.5)
Age (yr)41.1 ± 13.0
Sex, female72 (64.3)
Born in Israel84 (75.0)
Family status
Married59 (52.7)
Divorced13 (11.6)
Widowed2 (1.8)
Single38 (33.9)
High school64 (57.1)
More than high school48 (42.9)
BMI (kg/m2)42.5 ± 5.3
Dyslipidemia3 (2.7)
Hypertension39 (34.8)
Ischemic heart disease5 (4.5)
Diabetes mellitus 222 (19.6)
NAFLD63 (56.3)
Colorectal cancer3 (2.7)
Past surgery7 (6.3)
PPIs14 (12.5)
Iron supplements16 (14.3)
Aspirin11 (9.8)
Insulin8 (7.1)
Anti-diabetic medications14 (12.5)
NSAIDs8 (7.1)
Oral contraceptives6 (5.4)

Values are presented as mean ± standard deviation or n (%).

FBDs, functional bowel disorders; IBS, irritable bowel syndrome; FC, functional constipation; FDi, functional diarrhea; UFBD, unspecified functional bowel disorder; BMI, body mass index; NAFLD, non-alcoholic fatty liver disease; PPIs, proton pump inhibitors; NSAIDs, non-steroidal anti-inflammatory drugs.

Development of FBDs after bariatric surgery

A total of 68 patients underwent surgery and completed the postoperative questionnaire. Among the 61 patients for whom BMI data were available, the average postoperative BMI was 28.7 ± 4.9 kg/m2, with a mean reduction in BMI of 13.6 ± 4.3 kg/m2. An increase was observed in the frequency of IBS following surgery (from 1.5% to 8.8%, P = 0.06). In turn, no significant changes were noted in the prevalence of FC (4.4% pre-surgery vs. 2.9% post-surgery, P = 1.00), FDi (16.2% vs. 20.6%, P = 0.65), UFBD (14.7% vs. 11.8%, P = 0.41), or FBDs overall (36.8% vs. 44.1%, P = 0.44) (Fig. 2). We then examined predisposing factors for the development of FBDs in general. The frequency of previous abdominal surgery was significantly higher among patients who experienced FBDs postoperatively (16.7% vs. 0%, P = 0.01) (Table 2). However, a multivariable analysis incorporating age, sex, BMI, previous abdominal surgery, and family status did not reveal any significant risk factors for the development of FBDs following surgery.

Table 2 . Demographic and Medical Characteristics of Patients with Obesity Who Underwent Bariatric Surgery, Comparing Those with and without Postoperative FBD.

ParameterAll patients who underwent surgery (n = 68)With postoperative FBD (n = 30)Without postoperative FBD (n = 38)P-value
Age (yr)41.8 ± 12.641.5 ± 12.641.95 ± 12.70.82
Sex, female46 (67.6)19 (63.3)27 (71.1)0.49
Born in Israel48 (70.6)21 (70.0)27 (71.1)0.96
Family status
Married39 (57.4)17 (56.7)22 (57.9)0.92
Divorced7 (10.3)5 (16.7)2 (5.3)0.12
Widowed2 (2.9)0 (0.0)2 (5.3)0.20
Single20 (29.4)8 (26.7)12 (31.6)0.69
High school35 (51.5)15 (50.0)20 (52.6)0.83
More than high school33 (48.5)15 (50.0)18 (47.4)0.83
BMI (kg/m2)*42.49 ± 4.643.90 ± 5.241.37 ± 3.70.47
Hypertension25 (36.8)11 (36.7)14 (36.8)0.99
Ischemic heart disease3 (4.4)2 (6.7)1 (2.6)0.42
Diabetes mellitus 215 (22.1)9 (30.0)6 (15.8)0.16
NAFLD43 (63.2)17 (56.7)26 (68.4)0.32
Prior abdominal surgery5 (7.4)5 (16.7)0 (0.0)0.01
PPI7 (10.3)4 (13.3)3 (7.9)0.70
Iron supplements11 (16.2)6 (20.0)5 (13.2)0.15
Aspirin6 (8.8)3 (10.0)3 (7.9)0.76
Insulin6 (8.8)4 (13.3)2 (5.3)0.14
Anti-diabetic medications9 (13.2)4 (13.3)5 (13.2)0.13
NSAIDs5 (7.4)4 (13.3)1 (2.6)0.16
Type of surgery
MGB42 (61.8)17 (56.7)25 (65.8)0.11
REYGB5 (7.4)2 (6.7)3 (7.9)0.90
LSG21 (30.9)11 (36.7)10 (26.3)0.16

Values are presented as mean ± standard deviation or n (%).

FBDs, functional bowel disorders; BMI, body mass index; NAFLD, non-alcoholic fatty liver disease; PPI, proton pump inhibitor; NSAIDs, non-steroidal anti-inflammatory drugs; MGB, mini-gastric bypass; RYGB, Roux-En-Y gastric bypass; LSG, laparoscopic sleeve gastrectomy.

*Postoperative BMI was retrieved and computed for 61 patients.

Figure 2. Frequencies of FBDs before and after surgery. FBDs, functional bowel disorders; IBS, irritable bowel syndrome; FC, functional constipation; FDi, functional diarrhea; UFBD, unspecified functional bowel disorder.

Among the patients who underwent surgery, 37% developed new FBD postoperatively (Fig. 3). Non-alcoholic fatty liver disease (NAFLD) was less prevalent in the cohort that developed new FBD than among patients who did not (31.3% vs. 77.8%, P = 0.01) (Supplementary Table 2). Furthermore, a multivariable analysis that considered age, sex, BMI, and NAFLD revealed an inverse relationship between NAFLD and the emergence of new FBDs (odds ratio, 11.4; 95% confidence interval, 2.2–57.3, P = 0.003). Notably, in 44% of patients with preoperative FBD, the symptoms were no longer present following surgery. Type 2 diabetes mellitus (T2DM) was found to be relatively common among patients whose symptoms did not resolve (35.7% vs. 0%, P = 0.04) (Supplementary Table 3). However, a multivariable analysis that included age, sex, BMI, and DM indicated no statistically significant risk factors for the persistence of FBDs after bariatric surgery. Additionally, a subgroup analysis stratified by the type of bariatric surgery (bypass vs. non-bypass) revealed no significant differences in the presence of IBS or other FBDs before or after surgery.

Figure 3. Changes in overall FBD status from before to after surgery. FBDs, functional bowel disorders.

In this prospective study, the respective prevalence rates of FBDs and IBS among obese candidates for bariatric surgery were 37.5% and 2.7%, respectively. Furthermore, our findings suggest that bariatric surgery may pose a risk for the development of IBS, but not for other FBDs. Interestingly, NAFLD was found to be inversely associated with the emergence of new FBDs following surgery. As mentioned earlier, we did not analyze UGI functional disorders, as their symptoms can arise from the surgical procedures performed.

Our cohort, consisting of 112 candidates for bariatric surgery, had a mean BMI of 41.1 ± 13.0 kg/m2. The majority were female (64.3%), with over half being married (52.7%) and having a high school education (57.1%). Additionally, we observed high rates of obesity-related comorbidities, including hypertension (34.8%), NAFLD (56.3%), and T2DM (19.6%). The profile of our group resembles those described in other large studies of bariatric surgery candidates.19,3135 This similarity may facilitate the comparison of our results with findings from other series investigating FBDs.

Intriguingly, among our series of bariatric surgery candidates, risk factors for FBDs included female sex and single status. In contrast, a history of divorce was significantly more common among the patients with obesity who did not have FBDs. Although female sex is a recognized risk factor for FBDs,11 the influence of marital status on the emergence of these disorders remains unclear, with the literature presenting mixed findings.18,36 Other established risk factors for the development of FBDs, such as younger age and higher educational attainment, were not associated with the presence of FBDs in our cohort.12,37,38

Few studies have explored the relationship between obesity and the broad range of FBDs. Two retrospective studies have identified an association between FDi and increased BMI. In these studies, the rate of FDi was greater than in our series (20% vs. 5.4%).39,40 Two key factors may account for this discrepancy. First, the abdominal symptoms in those studies were based on patient reports, as opposed to our study, which utilized validated Rome III questionnaires. Second, the mean BMI of our cohort was higher than that of these studies, complicating the comparison of outcomes. FC and UFBD have been reported to occur in as many as 60% and 30% of overweight adults, respectively—rates considerably higher than those found in our study.41,42 However, other research has demonstrated no link between FC, UFBD, and obesity.39,40 These conflicting findings could stem from variations in study methodology and the retrospective nature of the research. Separately, Schneck et al18 conducted a prospective study among morbidly obese candidates for bariatric surgery and reported a sharply higher prevalence of IBS compared to our findings (30% vs. 2.7%). Although the study design and patient populations were similar in both studies, the differences in IBS prevalence might be partially due to geographical, cultural, and temporal factors.

The pathophysiology of postoperative abdominal symptoms may be attributed to alterations in the anatomy of the digestive tract, hormonal fluctuations, dumping syndromes, and the volume of consumed nutrients, all of which promote changes to the microbiome.43 Other exacerbating factors could include changes in intestinal permeability, gut-immune function, gut motility, visceral sensitivity, brain-gut interactions, and psychosocial status.44 Consequently, it is logical to assume that FBDs would be more common among individuals who have undergone bariatric surgery.

In our cohort, the rate of IBS after surgery (8.8%) was higher than that before (1.5%, P = 0.06). No significant difference was observed in the frequency of FBDs before and after surgery (36.8% vs. 44.1%, P = 0.44), and no significant risk factors were identified for the development of FBDs following surgery. The relationship between bariatric procedures and FBDs has been discussed in several studies, which have produced varying results. Post-surgery IBS has been reported by 24% to 29.1% of patients, with a higher frequency among women than men.23,24 Research also indicates that only 18.5% of patients who experienced chronic abdominal pain after surgery had reported pain prior to the procedure.23,26,27 However, these studies did not apply the Rome III consensus for diagnosis. In line with our findings, a recent Norwegian study that was based on the Rome III criteria revealed a significant increase in IBS symptoms following RYGB surgery, with rates rising from 12% to 26%.25 Earlier research indicated a significant rise in FC at 6 months after bariatric surgery, affecting nearly one-quarter of patients.24,45,46 Furthermore, FDi has been reported in nearly half of patients after surgery, representing a substantial increase from the preoperative rate.33,47 The frequencies of FDi and FC reported in these studies were considerably higher than those in our cohort. The differences and variability between studies may be due to factors such as differing sampling methodologies, regional variations in obesity, and the lack of standardized definitions for FBDs.

Our findings unexpectedly revealed an inverse relationship between NAFLD and the emergence of IBS following surgery. This stands in contrast to a cross-sectional study involving 100 consecutive patients with IBS, which reported a high NAFLD prevalence of 74%. In that study, moderate to severe NAFLD and metabolic syndrome were identified as independent predictors of moderate to severe IBS.48 However, the study was not conducted prospectively. The link between NAFLD and FBDs is currently being explored, with factors such as innate immunity, the gut microbiota, and intestinal motility suspected to play a role in their common pathogenesis.49 Intriguingly, our research identified T2DM as a risk factor for the persistence of IBS after bariatric surgery. Prior research has shown that approximately 70% of individuals with diabetes experience at least one gastrointestinal symptom.50 Furthermore, the prevalence of prediabetes has been found to be higher in patients with IBS compared to matched controls.51 Glucose control and IBS are closely linked. Hyperglycemia can disrupt gastric and small intestinal motility, potentially through inhibition of vagal-cholinergic neural pathways or by altering serum osmolality and gastrointestinal peptide secretion.52 Conversely, disorders of gastrointestinal motility, such as IBS, can lead to postprandial glycemic dysregulation.53

Our study had several limitations. First, the assessment of symptoms is inherently subjective and can be influenced by bias. To mitigate this issue, we employed a validated questionnaire that included recurrent symptom-specific questions. Second, candidates for bariatric surgery may have underreported their symptoms due to concerns that such disclosures could impact their eligibility for the procedure. To address this, the interviewer reassured participants regarding these concerns prior to completion of the questionnaire. Third, the research was carried out at a single center, raising the possibility of selection bias. Nonetheless, our center is a tertiary hospital, and the patients referred to our obesity and pre-surgery clinic come from a wide range of sociodemographic and clinical backgrounds, which is reflective of the broader population in Israel. Furthermore, the characteristics of our study group are consistent with those reported in other large series, as previously discussed. Fourth, the sample size of our study was relatively small, which may not have provided sufficient power to detect differences in the rates of IBS and FBDs before and after surgery. Fifth, the follow-up period was limited to 6 months post-surgery, which restricted our ability to explore long-term outcomes. The major strengths of this study lie in its prospective nature, accurate methodology, and contribution of new insights to the existing body of knowledge regarding the emergence of FBDs following bariatric surgery.

In conclusion, our findings suggest that bariatric surgery may elevate the risk of developing IBS, although it does not appear to increase the risk of other FBDs. Further research is required to clarify this relationship and to identify risk factors for FBDs following bariatric surgery, with the aim of potentially mitigating these risks before the procedure.

The datasets generated and analyzed in this study are not publicly available due to privacy and ethical considerations. However, they can be obtained from the corresponding author upon reasonable request.

No potential conflict of interest relevant to this article was reported.

  1. Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. 2017;66:1075-82.
    Pubmed CrossRef
  2. Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology. 2021;160:99-114.e3.
    Pubmed CrossRef
  3. Sperber AD, Shvartzman P, Friger M, Fich A. A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the 'true' prevalence of irritable bowel syndrome? Eur J Gastroenterol Hepatol. 2007;19:441-7.
    Pubmed CrossRef
  4. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40:1023-34.
    Pubmed CrossRef
  5. Pimentel M, Lembo A. Microbiome and its role in irritable bowel syndrome. Dig Dis Sci. 2020;65:829-39.
    Pubmed CrossRef
  6. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7:163-73.
    Pubmed CrossRef
  7. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011;46:421-31.
    Pubmed CrossRef
  8. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain. 2009;146:41-6.
    Pubmed KoreaMed CrossRef
  9. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62:159-76.
    Pubmed KoreaMed CrossRef
  10. Dupont HL. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther. 2014;39:1033-42.
    Pubmed CrossRef
  11. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712-21.e4.
    Pubmed CrossRef
  12. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:991-1000.
    Pubmed CrossRef
  13. Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil. 2012;18:258-68.
    Pubmed KoreaMed CrossRef
  14. Organisation for Economic Co-operation, Development (OECD). .
  15. GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13-27.
    Pubmed KoreaMed CrossRef
  16. Pickett-Blakely O. Obesity and irritable bowel syndrome: a comprehensive review. Gastroenterol Hepatol (N Y). 2014;10:411-6.
  17. Ho W, Spiegel BM. The relationship between obesity and functional gastrointestinal disorders: causation, association, or neither? Gastroenterol Hepatol (N Y). 2008;4:572-8.
  18. Schneck AS, Anty R, Tran A, Hastier A, Amor IB, Gugenheim J, et al. Increased prevalence of irritable bowel syndrome in a cohort of French morbidly obese patients candidate for bariatric surgery. Obes Surg. 2016;26:1525-30.
    Pubmed CrossRef
  19. Welbourn R, Hollyman M, Kinsman R, Dixon J, Liem R, Ottosson J, et al. Bariatric surgery worldwide: baseline demographic description and one-year outcomes from the fourth IFSO global registry report 2018. Obes Surg. 2019;29:782-95.
    Pubmed CrossRef
  20. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724-37; Erratum in: JAMA. 2005;293:1728.
    Pubmed CrossRef
  21. Yska JP, van Roon EN, de Boer A, Leufkens HG, Wilffert B, de Heide LJ, et al. Remission of type 2 diabetes mellitus in patients after different types of bariatric surgery: a population-based cohort study in the United Kingdom. JAMA Surg. 2015;150:1126-33.
    Pubmed CrossRef
  22. Driscoll S, Gregory DM, Fardy JM, Twells LK. Long-term health-related quality of life in bariatric surgery patients: a systematic review and meta-analysis. Obesity (Silver Spring). 2016;24:60-70.
    Pubmed CrossRef
  23. Høgestøl IK, Chahal-Kummen M, Eribe I, Brunborg C, Stubhaug A, Hewitt S, et al. Chronic abdominal pain and symptoms 5 years after gastric bypass for morbid obesity. Obes Surg. 2017;27:1438-45.
    Pubmed CrossRef
  24. Roberson EN, Gould JC, Wald A. Urinary and fecal incontinence after bariatric surgery. Dig Dis Sci. 2010;55:2606-13.
    Pubmed CrossRef
  25. Blom-Høgestøl IK, Aasbrenn M, Chahal-Kummen M, Brunborg C, Eribe I, Kristinsson J, et al. Irritable bowel syndrome-like symptoms and health related quality of life two years after Roux-en-Y gastric bypass - a prospective cohort study. BMC Gastroenterol. 2019;19:204.
    Pubmed KoreaMed CrossRef
  26. El Labban S, Safadi B, Olabi A. The effect of Roux-en-Y gastric bypass and sleeve gastrectomy surgery on dietary intake, food preferences, and gastrointestinal symptoms in post-surgical morbidly obese Lebanese subjects: a cross-sectional pilot study. Obes Surg. 2015;25:2393-9.
    Pubmed CrossRef
  27. Gribsholt SB, Pedersen AM, Svensson E, Thomsen RW, Richelsen B. Prevalence of self-reported symptoms after gastric bypass surgery for obesity. JAMA Surg. 2016;151:504-11.
    Pubmed CrossRef
  28. Thompson WG, Drossman DA, Talley NJ, Walker L, Whitehead WE. Rome III diagnostic questionnaire for the adult functional GI disorders (including alarm questions) and scoring algorithm. In: Drossman DA, Cprazzoaro E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, et al, editors. Rome III: the functional gastrointestinal disorders. Degnon Associates, Inc.; 2006, p. 917-51.
  29. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology. 2013;145:1262-70.e1.
    Pubmed CrossRef
  30. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480-91; Erratum in: Gastroenterology. 2006;131:688.
    Pubmed CrossRef
  31. Friedenberg FK, Xanthopoulos M, Foster GD, Richter JE. The association between gastroesophageal reflux disease and obesity. Am J Gastroenterol. 2008;103:2111-22.
    Pubmed CrossRef
  32. Ogden CL, Fakhouri TH, Carroll MD, Hales CM, Fryar CD, Li X, et al. Prevalence of obesity among adults, by household income and education - United States, 2011-2014. MMWR Morb Mortal Wkly Rep. 2017;66:1369-73.
    Pubmed KoreaMed CrossRef
  33. Potoczna N, Harfmann S, Steffen R, Briggs R, Bieri N, Horber FF. Bowel habits after bariatric surgery. Obes Surg. 2008;18:1287-96.
    Pubmed CrossRef
  34. Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes. 2014;7:587-91.
    Pubmed KoreaMed CrossRef
  35. Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes. 2011;18:139-43.
    Pubmed KoreaMed CrossRef
  36. Han SH, Lee OY, Bae SC, Lee SH, Chang YK, Yang SY, et al. Prevalence of irritable bowel syndrome in Korea: population-based survey using the Rome II criteria. J Gastroenterol Hepatol. 2006;21:1687-92.
    Pubmed CrossRef
  37. Agréus L, Svärdsudd K, Nyrén O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995;109:671-80.
    Pubmed CrossRef
  38. Long Y, Huang Z, Deng Y, Chu H, Zheng X, Yang J, et al. Prevalence and risk factors for functional bowel disorders in South China: a population based study using the Rome III criteria. Neurogastroenterol Motil. 2017;29:e12897.
    Pubmed CrossRef
  39. Delgado-Aros S, Locke GR 3rd, Camilleri M, Talley NJ, Fett S, Zinsmeister AR, et al. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol. 2004;99:1801-6.
    Pubmed CrossRef
  40. Talley NJ, Quan C, Jones MP, Horowitz M. Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort. Neurogastroenterol Motil. 2004;16:413-9.
    Pubmed CrossRef
  41. Pourhoseingholi MA, Kaboli SA, Pourhoseingholi A, Moghimi-Dehkordi B, Safaee A, Mansoori BK, et al. Obesity and functional constipation; a community-based study in Iran. J Gastrointestin Liver Dis. 2009;18:151-5.
  42. Fysekidis M, Bouchoucha M, Bihan H, Reach G, Benamouzig R, Catheline JM. Prevalence and co-occurrence of upper and lower functional gastrointestinal symptoms in patients eligible for bariatric surgery. Obes Surg. 2012;22:403-10.
    Pubmed CrossRef
  43. Aron-Wisnewsky J, Doré J, Clement K. The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol Hepatol. 2012;9:590-8.
    Pubmed CrossRef
  44. Chey WD, Eswaran S, Kurlander J. JAMA patient page. Irritable bowel syndrome. JAMA. 2015;313:982.
    Pubmed CrossRef
  45. Afshar S, Kelly SB, Seymour K, Woodcock S, Werner AD, Mathers JC. The effects of bariatric procedures on bowel habit. Obes Surg. 2016;26:2348-54.
    Pubmed KoreaMed CrossRef
  46. Kvehaugen AS, Farup PG. Changes in gastrointestinal symptoms and food tolerance 6 months following weight loss surgery: associations with dietary changes, weight loss and the surgical procedure. BMC Obes. 2018;5:29.
    Pubmed KoreaMed CrossRef
  47. Borbély YM, Osterwalder A, Kröll D, Nett PC, Inglin RA. Diarrhea after bariatric procedures: diagnosis and therapy. World J Gastroenterol. 2017;23:4689-700.
    Pubmed KoreaMed CrossRef
  48. Hasanain AFA, Abdel-Rahman ME, Ali AM, Abdel-Aal SM. Nonalcoholic fatty liver disease among patients with irritable bowel syndrome: prevalence and contribution to disease severity. Gastroenterol Hepatol Endosc. 2018;3:1-4.
  49. Scalera A, Di Minno MN, Tarantino G. What does irritable bowel syndrome share with non-alcoholic fatty liver disease? World J Gastroenterol. 2013;19:5402-20.
    Pubmed KoreaMed CrossRef
  50. Clouse RE, Lustman PJ. Gastrointestinal symptoms in diabetic patients: lack of association with neuropathy. Am J Gastroenterol. 1989;84:868-72.
  51. Gulcan E, Taser F, Toker A, Korkmaz U, Alcelik A. Increased frequency of prediabetes in patients with irritable bowel syndrome. Am J Med Sci. 2009;338:116-9.
    Pubmed CrossRef
  52. de Boer SY, Masclee AA, Lamers CB. Effect of hyperglycemia on gastrointestinal and gallbladder motility. Scand J Gastroenterol Suppl. 1992;194:13-8.
    Pubmed CrossRef
  53. Tao W, Dong X, Kong G, Fang P, Huang X, Bo P. Elevated circulating hsa-miR-106b, hsa-miR-26a, and hsa-miR-29b in type 2 diabetes mellitus with diarrhea-predominant irritable bowel syndrome. Gastroenterol Res Pract. 2016;2016:9256209.
    Pubmed KoreaMed CrossRef